Genflow Biosciences PLC Company Share Purchase by CEO (9885V)
August 15 2022 - 2:00AM
UK Regulatory
TIDMGENF
RNS Number : 9885V
Genflow Biosciences PLC
15 August 2022
15 August 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Company Share Purchase by CEO
Genflow Biosciences (LSE: GENF) , a UK-based biotechnology
company focused on longevity and the development of therapies to
counteract the effects of aging and diseases associated with
advanced age,
announces that it was notified on 08 August 2022, that Eric
Leire, a director of the Company, purchased the following Ordinary
Shares:
PDMR / Person Total Number Weighted Resultant Percentage
closely associated of Ordinary Average Price Shareholding Of The Total
Shares Purchased per Ordinary Voting Rights
Share of the Company
Eric Leire 106,000 0.028 120,414,999 41.17
------------------ --------------- -------------- ----------------
Notifications have been made in accordance with the requirements
of the EU Market Abuse Regulation in respect of the PDMRs and
further details can be found by following this link:
https://genflowbio.com/investors/news-releases/
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For further information please contact:
Genflow Biosciences
Dr Eric Leire via Tancredi +44 203 434 2330
Chief Executive
------------------------------
Clear Capital
------------------------------
Corporate Broker
+44 203 869 6086
Jonathan Critchley
Keith Swann +44 203 897 0981
------------------------------
Tancredi Intelligent Communication
Media Relations
------------------------------
Salamander Davoudi +44 7957 549 906
Helen Humphrey +44 7449 226 720
Benedetta Negri da Oleggio +44 7838 029 970
genflowbio@tancredigroup.com
------------------------------
About Genflow Biosciences
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno-associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase our understanding of the factors that
control and impact lifespan. Genflow researchs, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPURPRUPPUAA
(END) Dow Jones Newswires
August 15, 2022 02:00 ET (06:00 GMT)
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Apr 2023 to Apr 2024
